In recent years, GLP-1 receptor agonists, such as Novo Nordisk's Wegovy and Eli ... guidance to stop pharmacists distributing Rybelsus (Semaglutide) to new patients, due to supply issues.

Novo Nordisk's (NVO) weight loss drug semaglutide (Ozempic, Wegovy, Rybelsus) is linked to a rare eye condition called NAION ...

Semaglutide drugs now include rare vision risk warning as studies link long-term use to optic neuropathy, macular ...

Given the evidence, the committee has recommended that the labels for Novo Nordisk’s Wegovy and Ozempic be updated to include ...

The European Medicines Agency's safety committee has concluded that a potentially dangerous eye condition is a very rare side ...

Novo Nordisk's GLP-1 receptor agonist semaglutide has shown efficacy as a treatment for metabolic dysfunction-associated steatohepatitis (MASH) in a phase 3 trial, potentially teeing up US and ...

Novo Nordisk NVO has seen strong momentum in recent years, driven by the commercial success of its blockbuster semaglutide ...

During a session at the Heart in Diabetes CME Conference, speakers highlighted four papers recently published in Circulation ...